March 12th 2025
Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.
February 17th 2025
Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2
November 10th 2021Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.
Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs
October 15th 2021In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.